Quantum Genomics Société Anonyme (ALQGC.PA)
EUR 0.07
(0.0%)
EUR 0.07
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.87 Million EUR | 90.36% |
| 2022 | -29.81 Million EUR | -51.19% |
| 2021 | -19.41 Million EUR | -18.14% |
| 2020 | -14.67 Million EUR | -55.33% |
| 2019 | -10.61 Million EUR | 20.85% |
| 2018 | -13.54 Million EUR | -32.27% |
| 2017 | -10.26 Million EUR | -65.87% |
| 2016 | -6.18 Million EUR | -44.41% |
| 2015 | -4.25 Million EUR | -78.39% |
| 2014 | -2.45 Million EUR | -27.02% |
| 2013 | -1.89 Million EUR | -80.62% |
| 2012 | -1.04 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.14 Million EUR | 0.0% |
| 2023 Q4 | -886.75 Thousand EUR | 0.0% |
| 2023 FY | - EUR | 89.45% |
| 2023 Q2 | -1.99 Million EUR | 0.0% |
| 2022 Q4 | -20.32 Million EUR | 0.0% |
| 2022 Q2 | -12.65 Million EUR | 0.0% |
| 2022 FY | - EUR | -51.19% |
| 2021 FY | - EUR | -18.14% |
| 2021 Q4 | -9.75 Million EUR | 0.0% |
| 2021 Q2 | -7.46 Million EUR | 0.0% |
| 2020 FY | - EUR | -55.33% |
| 2020 Q2 | -5.94 Million EUR | 0.0% |
| 2020 Q4 | -8.72 Million EUR | 0.0% |
| 2019 FY | - EUR | 20.85% |
| 2019 Q2 | -5.31 Million EUR | 0.0% |
| 2019 Q4 | -5.43 Million EUR | 0.0% |
| 2018 Q4 | -6.78 Million EUR | 0.0% |
| 2018 FY | - EUR | -32.27% |
| 2018 Q2 | -6.79 Million EUR | 0.0% |
| 2017 Q2 | -4.48 Million EUR | 0.0% |
| 2017 FY | - EUR | -65.87% |
| 2017 Q4 | -5.77 Million EUR | 0.0% |
| 2016 FY | - EUR | -44.41% |
| 2016 Q4 | -3.12 Million EUR | 0.0% |
| 2016 Q2 | -3.06 Million EUR | 0.0% |
| 2015 Q4 | -2.35 Million EUR | 0.0% |
| 2015 FY | - EUR | -78.39% |
| 2015 Q2 | -1.92 Million EUR | 0.0% |
| 2014 Q2 | -1.36 Million EUR | 0.0% |
| 2014 Q4 | -1.04 Million EUR | 0.0% |
| 2014 FY | - EUR | -27.02% |
| 2013 Q3 | -473.6 Thousand EUR | 50.86% |
| 2013 Q1 | -473.6 Thousand EUR | 0.0% |
| 2013 Q2 | -963.77 Thousand EUR | -103.5% |
| 2013 Q4 | -929.76 Thousand EUR | -96.32% |
| 2013 FY | - EUR | -80.62% |
| 2012 Q3 | -261.67 Thousand EUR | 0.0% |
| 2012 Q1 | -261.67 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | -473.6 Thousand EUR | -80.99% |
| 2012 Q2 | -261.67 Thousand EUR | 0.0% |
| 2011 Q4 | -261.67 Thousand EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | 12.66% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 97.843% |
| Adocia SA | -22.73 Million EUR | 87.359% |
| Aelis Farma SA | -6.34 Million EUR | 54.727% |
| Biophytis S.A. | -13.8 Million EUR | 79.184% |
| Advicenne S.A. | -6.24 Million EUR | 53.98% |
| genOway Société anonyme | 6.35 Million EUR | 145.246% |
| IntegraGen SA | -52.5 Thousand EUR | -5372.982% |
| Medesis Pharma S.A. | -3.84 Million EUR | 25.265% |
| Neovacs S.A. | -8.44 Million EUR | 65.992% |
| NFL Biosciences SA | -4.04 Million EUR | 29.038% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 4061.781% |
| Sensorion SA | -22.31 Million EUR | 87.122% |
| Theranexus Société Anonyme | -7.38 Million EUR | 61.102% |
| TME Pharma N.V. | -5.07 Million EUR | 43.346% |
| Valbiotis SA | -6.95 Million EUR | 58.685% |
| TheraVet SA | -517.33 Thousand EUR | -455.438% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 84.809% |
| argenx SE | -199.5 Million EUR | 98.56% |
| BioSenic S.A. | -6.79 Million EUR | 57.718% |
| Celyad Oncology SA | -7.76 Million EUR | 62.985% |
| DBV Technologies S.A. | -79.53 Million EUR | 96.387% |
| Galapagos NV | 51.03 Million EUR | 105.63% |
| Genfit S.A. | -28.05 Million EUR | 89.756% |
| GeNeuro SA | -14.31 Million EUR | 79.931% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 80.818% |
| Innate Pharma S.A. | -7.57 Million EUR | 62.081% |
| Inventiva S.A. | -101.84 Million EUR | 97.179% |
| MaaT Pharma SA | -19.74 Million EUR | 85.443% |
| MedinCell S.A. | -20.04 Million EUR | 85.666% |
| Nanobiotix S.A. | -34.01 Million EUR | 91.553% |
| Onward Medical N.V. | -35.23 Million EUR | 91.845% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 35.185% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 87.649% |
| Oxurion NV | -16.72 Million EUR | 82.823% |
| Pharming Group N.V. | 4.98 Million EUR | 157.689% |
| Poxel S.A. | -12.17 Million EUR | 76.406% |
| GenSight Biologics S.A. | -21.73 Million EUR | 86.776% |
| Transgene SA | -27.02 Million EUR | 89.367% |
| Financière de Tubize SA | 184.57 Thousand EUR | 1656.843% |
| UCB SA | 1.26 Billion EUR | 100.226% |
| Valneva SE | -64.51 Million EUR | 95.546% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 89.865% |